Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02695212 · ClinicalTrials.gov registry record · Phase 2

Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa

A Phase 2 study of Hidradenitis Suppurativa, sponsored by Florida Academic Dermatology Centers.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target
1
Study location

NCT02695212: Completed Phase 2 study of Hidradenitis Suppurativa, sponsored by Florida Academic Dermatology Centers.

NCT02695212 is a Phase 2 study of Hidradenitis Suppurativa that has completed, run by Florida Academic Dermatology Centers. The registered enrollment target is 20 participants, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02695212, a Phase 2 study of Hidradenitis Suppurativa, has completed, sponsored by Florida Academic Dermatology Centers.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to evaluate the safety and efficacy of Apremilast in subjects with moderate Hidradenitis Suppurativa (HS).

Primary Outcome

defined as a 30% reduction in the total number of abscess and inflammatory nodule count with a 50% reduction as an exploratory endpoint..

Conditions Studied

Hidradenitis Suppurativa

Interventions

  • DRUG Apremilast

Study Locations (1)

Florida

  • Florida Academic Dermatology Centers - Coral Gables

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2016-07
Est. Completion 2017-08
Phase Phase 2
Florida Academic Dermatology Centers

2 total trials

What the finished NCT02695212 record still lists

NCT02695212 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which Apremilast is the first listed.

NCT02695212 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT02695212 about?

NCT02695212 is a clinical study titled "Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa". The primary objective of this study is to evaluate the safety and efficacy of Apremilast in subjects with moderate Hidradenitis Suppurativa (HS).

What is the current status of trial NCT02695212?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-07. Estimated completion is 2017-08.

What conditions does trial NCT02695212 study?

This clinical trial studies the following conditions: Hidradenitis Suppurativa.

What interventions are being tested in trial NCT02695212?

The interventions under investigation include: Apremilast (DRUG).

Who is sponsoring clinical trial NCT02695212?

This trial is sponsored by Florida Academic Dermatology Centers, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02695212 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hidradenitis Suppurativa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02695212's enrollment target sits among peer trials

20 41st of 52 higher than 9 of 52 other Hidradenitis Suppurativa trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02695212, the US trial registry maintained by the National Library of Medicine. NCT02695212 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.